(PresseBox)
(Heidelberg,
2017-05-16)
Relapse is now the main cause of death for breast cancer patients. Researchers at EMBL have found that, in mice, the tumour cells that survive therapy and eventually cause a relapse have specific traits that distinguish them from healthy cells. In a study published today in the Journal of Clinical Investigation, the scientists revealed that two of these traits could be promising targets for treatments to reduce tumour recurrence in breast cancer patients.
“Our results suggest that residual cells retain an “oncogenic memory” that could be exploited to develop drugs against breast cancer recurrence,” says Martin Jechlinger, who led the research at EMBL.
Thanks to improvements in primary care, more and more breast cancer patients survive the initial tumour. Although treatments like chemotherapy and mastectomies aim to eliminate all of a patient’s tumour cells, breast cancer cells that survive these initial therapies often reinitiate growth, causing a relapse further down the line. These residual cells are difficult to identify and analyse because, until they relapse, they look and act as normal cells. This means breast cancer relapse has remained largely unexplored, and makes it difficult to predict if and when a patient will experience relapse.
Residual cells have a chemical signature
“We found that residual cells have molecular traits that clearly distinguish them from normal breast tissue, and seem to cause relapse,” Jechlinger explains. “When we treated those features in mice, their tumours were less likely to recur.”
Jechlinger and colleagues found that, compared to healthy cells, residual cancer cells have altered lipid metabolism. This contributes to maintaining high levels of “reactive oxygen species” — chemically reactive molecules that are known to damage DNA. The scientists think that this damage triggers the relapse.
The team then compared the findings from the mouse model to samples from breast cancer patients, thanks to collaborators at the European Institute of Oncology in Milan, Italy, and the National Centre for Tumour Diseases in Heidelberg, Germany. The two sets of results were consistent, which suggests they could be useful to understand and treat breast cancer recurrence in humans.
“Every patient is different and every story is unique, but our results suggest that lipid metabolism is an exciting therapeutic target to reduce breast cancer recurrence,” says Kristina Havas, who carried out much of the research in Jechlinger’s lab at EMBL.
Press release BoxID: 854808 (EMBL Heidelberg)
- EMBL Heidelberg
- Meyerhofstraße 1
- 69117 Heidelberg
- http://www.embl.de
- Contact person
- Sonia Furtado Neves
- +49 (6221) 387-8263
QrCode
What its a QR code?
Three steps: Scanning of a QR code: Find your way to a press release without typing. Use the QR code on the print version of a press release to get redirected to the corresponding page on PresseBox.
How does scanning a QR code work? Just follow these simple steps.
Everything you need is an internet-enabled mobile phone or smartphone with a built-in camera and a QR code reading software.
QR stands for Quick Response - with one step you can quickly reach a website. QR codes work like bar codes, which you can find on your milk carton, for example. A software decrypts the QR code and directs you to a web page - so you do not even need to know the web address to reach it.
Download and print your digital press kit now
Please send the following information to my email address:
Cell changes drive breast cancer relapse
Researchers identify features of residual breast cancer cells that suggest new approaches for preventing relapse
EMBL Heidelberg
EMBL is Europe's flagship laboratory for the life sciences. We are an intergovernmental organisation established in 1974 and are supported by over 20 member states.
EMBL performs fundamental research in molecular biology, studying the story of life. We offer services to the scientific community; train the next generation of scientists and strive to integrate the life sciences across Europe.
We are international, innovative and interdisciplinary. We are more than 1600 people, from over 80 countries, operating across five sites in Grenoble (France), Hamburg (Germany), Heidelberg (Germany), Hinxton (UK) and Monterotondo (Italy). Our scientists work in independent groups and conduct research and offer services in all areas of molecular biology.
Our research drives the development of new technology and methods in the life sciences. We work to transfer this knowledge for the benefit of society.
EMBL performs fundamental research in molecular biology, studying the story of life. We offer services to the scientific community; train the next generation of scientists and strive to integrate the life sciences across Europe.
We are international, innovative and interdisciplinary. We are more than 1600 people, from over 80 countries, operating across five sites in Grenoble (France), Hamburg (Germany), Heidelberg (Germany), Hinxton (UK) and Monterotondo (Italy). Our scientists work in independent groups and conduct research and offer services in all areas of molecular biology.
Our research drives the development of new technology and methods in the life sciences. We work to transfer this knowledge for the benefit of society.
